WT1 HLA class II-binding peptides and compositions and methods comprising same
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07K-014/47
A61K-039/00
A61K-038/00
출원번호
US-0991442
(2016-01-08)
등록번호
US-10221224
(2019-03-05)
발명자
/ 주소
Scheinberg, David A.
Pinilla-Ibarz, Javier
May, Rena
출원인 / 주소
MEMORIAL SLOAN KETTERING CANCER CENTER
대리인 / 주소
Cohen, Mark S.
인용정보
피인용 횟수 :
0인용 특허 :
54
초록
This invention provides WT1 peptides and methods of treating, reducing the incidence of, and inducing immune responses against a WT1-expressing cancer, comprising same.
대표청구항▼
1. A nucleic acid encoding a Wilms tumor 1 (WT1) peptide consisting of the amino acid sequence RSDELVRHHNMHQRNMTKL (SEQ ID No: 2) or PGCNKRYFKLSHLQMHSRKHTG (SEQ ID No: 4). 2. An expression vector comprising the nucleic acid of claim 1. 3. A method of inducing an anti-mesothelioma immune response in
1. A nucleic acid encoding a Wilms tumor 1 (WT1) peptide consisting of the amino acid sequence RSDELVRHHNMHQRNMTKL (SEQ ID No: 2) or PGCNKRYFKLSHLQMHSRKHTG (SEQ ID No: 4). 2. An expression vector comprising the nucleic acid of claim 1. 3. A method of inducing an anti-mesothelioma immune response in a subject, the method comprising the step of contacting said subject with the nucleic acid expression vector of claim 2, thereby inducing an anti-mesothelioma immune response in a subject. 4. A method of treating a subject with a mesothelioma, or reducing an incidence of a mesothelioma or its relapse, the method comprising the step of administering to said subject the nucleic acid expression vector of claim 2, thereby treating a subject with a mesothelioma, or reducing an incidence of a mesothelioma or its relapse. 5. A method of treating a subject with a WT1-expressing cancer, the method comprising administering to said subject the expression vector of claim 2, thereby treating a subject with a WT1-expressing cancer. 6. The method of claim 5, wherein said WT1-expressing cancer is a leukemia, a desmoplastic small round cell tumor, a gastric cancer, a colon cancer, a lung cancer, a breast cancer, a germ cell tumor, an ovarian cancer, a uterine cancer, a thyroid cancer, a liver cancer, a renal cancer, a kaposi's sarcoma, a sarcoma, or a hepatocellular carcinoma. 7. The method of claim 5, wherein said WT1-expressing cancer is a Wilms' tumor, an acute myelogenous leukemia (AML), a myelodysplastic syndrome (MDS), a mesothelioma or a non-small cell lung cancer (NSCLC). 8. A method of reducing an incidence of a WT1-expressing cancer, or its relapse, in a subject, the method comprising administering to said subject the expression vector of claim 2, thereby reducing an incidence of a WT1-expressing cancer, or its relapse, in a subject. 9. The method of claim 8, wherein said WT1-expressing cancer is a leukemia, a desmoplastic small round cell tumor, a gastric cancer, a colon cancer, a lung cancer, a breast cancer, a germ cell tumor, an ovarian cancer, a uterine cancer, a thyroid cancer, a liver cancer, a renal cancer, a kaposi's sarcoma, a sarcoma, or a hepatocellular carcinoma. 10. The method of claim 8, wherein said WT1-expressing cancer is a Wilms' tumor, an acute myelogenous leukemia (AML), a myelodysplastic syndrome (MDS), mesothelioma or a non-small cell lung cancer (NSCLC). 11. A method of inducing the formation and proliferation of CTL specific for cells of a WT1-expressing cancer, the method comprising administering to said subject the expression vector of claim 2, thereby inducing the formation and proliferation of CTL specific for cells of a WT1-expressing cancer. 12. The method of claim 11, wherein said WT1-expressing cancer is a leukemia, a desmoplastic small round cell tumor, a gastric cancer, a colon cancer, a lung cancer, a breast cancer, a germ cell tumor, an ovarian cancer, a uterine cancer, a thyroid cancer, a liver cancer, a renal cancer, a kaposi's sarcoma, a sarcoma, or a hepatocellular carcinoma. 13. The method of claim 11, wherein said WT1-expressing cancer is a Wilms' tumor, an acute myelogenous leukemia (AML), a myelodysplastic syndrome (MDS), a mesothelioma or a non-small cell lung cancer (NSCLC). 14. A pharmaceutical composition comprising the expression vector of claim 2. 15. The expression vector of claim 2, wherein the vector is an attenuated viral vector or a Salmonella typhi vector. 16. The expression vector of claim 2, further encoding an immunomodulatory compound. 17. The expression vector of claim 16, wherein the immunomodulatory compound is a cytokine, chemokine, or complement component that enhances expression of immune system accessory or adhesion molecules, their receptors, or a combination thereof. 18. The expression vector of claim 16, wherein the immunomodulatory compound is any of interleukins 1 to 15 interferons alpha, beta or gamma, tumour necrosis factor, granulocyte-macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF), granulocyte colony stimulating factor (G-CSF), a chemokine such as neutrophil activating protein (NAP), macrophage chemoattractant and activating factor (MCAF), RANTES, or macrophage inflammatory peptides MIP-1a or MIP-1b. 19. A vaccine comprising the nucleic acid expression vector of claim 2. 20. The vaccine of claim 19 further comprising an adjuvant, carrier or antigen presenting cell. 21. The vaccine of claim 20 wherein the adjuvant is QS21, Freund's incomplete adjuvant, aluminum phosphate, aluminum hydroxide, BCG, alum, a growth factor, a cytokine, a chemokine, an interleukin, Montanide ISA 51, or GM-CSF.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (54)
Lynch David H. (Bainbridge Island WA), Adoptive immunotherapy with interleukin-7.
Hilton, Traci; Aung, Sandra; van de Ven, Rieneke; Paustian, Christopher; Moudgil, Tarsem; Dubay, Christopher; Twitty, Christopher; Hu, Hong-Ming; Fox, Bernard A., Allogeneic autophagosome-enriched composition for the treatment of disease.
Graddis, Thomas; Laus, Reiner; Diegel, Michael; Vidovic, Damir, Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease.
Gaiger, Alexander; Algate, Paul A.; Mannion, Jane; Clapper, Jonathan David; Wang, Aijun; Ordonez, Nadia; Carter, Lauren; McNeill, Patricia Dianne, Compositions and methods for the detection diagnosis and therapy of hematological malignancies.
Call Katherine M. ; Glaser Thomas M. ; Ito Caryn Y. ; Buckler Alan J. ; Pelletier Jerry,CAX ; Haber Daniel A. ; Rose Elise A. ; Housman David E. ; Breuning Wendy,CAX ; Darveau Andre,CAX, Localization and characterization of the Wilms' tumor gene.
Call Katherine M. ; Glaser Thomas M. ; Ito Caryn Y. ; Buckler Alan J. ; Pelletier Jerry,CAX ; Haber Daniel A. ; Rose Elise A. ; Housman David E. ; Bruening Wendy,CAX ; Darveau Andre,CAX, Localization and characterization of the Wilms' tumor gene.
Dubensky, Jr., Thomas W.; Brockstedt, Dirk G.; Hearst, John E.; Cook, David N., Modified free-living microbes, vaccine compositions and methods of use thereof.
Kang, Chang-Yuil; Ko, Hyun-Jeong; Lee, Jung-Mi; Kim, Yeon-Jeong, Vaccine comprising monocyte or immature myeloid cells (IMC) which were loaded with the ligand of natural killer T cell and antigen.
Herlyn Meenhard (Wynnewood PA) Morris Jennifer (Brookfield WI) Rauscher ; III Frank J. (Cranbury NJ) Rodeck Ulrich (Philadelphia PA), WT1 monoclonal antibodies and methods of use therefor.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.